Modality
Vaccine
MOA
FXIai
Target
GPRC5D
Pathway
Fibrosis
ALLALSPompe
Development Pipeline
Preclinical
~Dec 2019
→ ~Mar 2021
Phase 1
Jun 2021
Phase 1Current
NCT07950561
1,313 pts·ALS
2021-06→TBD·Recruiting
1,313 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P1
Recruit…
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07950561 | Phase 1 | ALS | Recruiting | 1313 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| Semazasiran | BeiGene | Phase 1 | PD-1 |